According to one study, patients who took orfoglipron had 12% average weight loss at its highest dose over 72 weeks
47 The phase 3 randomised controlled TRIUMPH-3 trial is currently underway to evaluate the effects of retatrutide in participants with obesity (BMI of 35 kg/m 2 and above) and established CVD, focusing on percentage change in body weight (clinical trial number NCT05882045
GLP-1 Agonists and Gastric Motility: The Core Connection As weve discussed, Zepbound (tirzepatide) works, in part, by slowing gastric emptying
Although nail fragility is often interpreted as a sign of micronutrient deficiency, it is a physiological finding in infants and does not require further evaluation
Eliquis helps reduce this risk
July 17, 2025 Exploring Hair Loss Solutions Hair loss affects millions of people, regardless of sex , and often becomes more noticeable with age, hormonal changes, or stress